Crossmark

Influence of Corticosteroid Use on Short- and Long-Term Outcomes of Biologic Therapy for Inflammatory Bowel Diseases

Published Online: 2022-01-30

Published Print: 2022-11

Authors

Sieber, Alexis

Aberra, Faten N.

Bonhomme, Brittaney

McKeever, Liam

Lewis, James D. https://orcid.org/0000-0003-3107-3862
License Information

Text and Data Mining valid from 2022-01-30

Version of Record valid from 2022-01-30
More Information

Article History

Received: 27 August 2021

Accepted: 6 December 2021

First Online: 30 January 2022

Declarations

:

: Authors' declaration of personal interests: (i) Dr. Lewis has served as a consultant or advisory board member for Merck, Janssen Pharmaceuticals, Bristol-Myers Squibb, Bridge Biotherapeutics, Entasis Therapeutics, Scipher Medicine and AbbVie. (ii) Dr. Lewis has served as a member of Data Monitoring Committees for Amgen, Pfizer, Gilead, Arena Pharmaceuticals, and Protagonist Therapeutics. (iii) Dr. Lewis has had research funding from Takeda Pharmaceuticals, Janssen Pharmaceuticals, AbbVie, and Nestle Health Science. (iv) Dr. Lewis has received honorarium for speaking in CME program sponsored by Nestle Health Science. (v) Dr. Aberra has had research funding from Janssen, AbbVie, and Pfizer. No other authors declare any potential conflicts of interest.

Document is current